BDBM50062599 3,5-Dimethyl-adamantan-1-ylamine EN300-123026 Namenda MEMANTINE CHEMBL807 US10214478, Compound memantine
- Kumamoto, T; Nakajima, M; Uga, R; Ihayazaka, N; Kashihara, H; Katakawa, K; Ishikawa, T; Saiki, R; Nishimura, K; Igarashi, K Design, synthesis, and evaluation of polyamine-memantine hybrids as NMDA channel blockers. Bioorg Med Chem 26: 603-608 (2018)
- Turcu, AL; Companys-Alemany, J; Phillips, MB; Patel, DS; Griñán-Ferré, C; Loza, MI; Brea, JM; Pérez, B; Soto, D; Sureda, FX; Kurnikova, MG; Johnson, JW; Pallàs, M; Vázquez, S Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease. Eur J Med Chem 236: (2022)
- Simoni, E; Daniele, S; Bottegoni, G; Pizzirani, D; Trincavelli, ML; Goldoni, L; Tarozzo, G; Reggiani, A; Martini, C; Piomelli, D; Melchiorre, C; Rosini, M; Cavalli, A Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J Med Chem 55: 9708-21 (2012)
- Busch, AE; Karbach, U; Miska, D; Gorboulev, V; Akhoundova, A; Volk, C; Arndt, P; Ulzheimer, JC; Sonders, MS; Baumann, C; Waldegger, S; Lang, F; Koepsell, H Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54: 342-52 (1998)
- Nepali, K; Hsu, TI; Hsieh, CM; Lo, WL; Lai, MJ; Hsu, KC; Lin, TE; Chuang, JY; Liou, JP Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. Eur J Med Chem 217: (2021)
- Rosini, M; Simoni, E; Caporaso, R; Basagni, F; Catanzaro, M; Abu, IF; Fagiani, F; Fusco, F; Masuzzo, S; Albani, D; Lanni, C; Mellor, IR; Minarini, A Merging memantine and ferulic acid to probe connections between NMDA receptors, oxidative stress and amyloid-? peptide in Alzheimer's disease. Eur J Med Chem 180: 111-120 (2019)
- Protective Effects of Compounds on Primary Cerebellum Granule Cells of Rats Isolated primary cerebellum granule cells of infant rats were inoculated in 96-well plates with 1.2×105/well by using 10% FBS+25 mM KCl+2 mM Glutamine+1% of double-antibody BME medium. After 24 hours, cytarabine with a final concentration of 10 iM was added to inhibit the proliferation of neurogliocyte cells. After the day 4, glucose with the final concentration of 5 mM was added every four days to complement energy metabolism and water evaporation of cells. The materials were placed in a cell incubator (37° C., 5% CO2) to be cultured for 10 days. A 200 iM of glutamate was used to induce the excitotoxic injury of the primary cerebellum granule cells, with test groups of normal control group, glutamate group, pretreatment groups with different memantine nitrate compounds, and pretreatment control group with memantine. In the testing groups, the compounds of NM-001, NM-002, NM-003, NM-004, NM-005, NM-008, NM-009, NM-011, NM-012 and memantine were respectively added. After pre-protection for 2 h, 200 iM of glutamate was added to induce cell damage for 24 h, and then MTT was added to culture for 4 h. The supernatant fraction was sucked, and 150 iL of DMSO was added to each well for dissolving. After blending with shaking, the light absorption values under 570 nm wavelength was measured with a microplate reader, and the viability of cells was calculated. Cell viability (%)=absorbance of different groups/absorbance of the normal control group×100%.